The U.S. Food and Drug Administration (FDA) approved Ozanimod, marketed under the brand name Zeposia, on March 25, 2020.

Alnylam Announces Successful Topline Results from HELIOS-B Phase 3 Trial of Vutrisiran, Showing Statistical Significance in Primary and All Secondary Endpoints in Both Combined and Monotherapy Groups.

The U.S. Food and Drug Administration (FDA) approved Isatuximab, under the brand name Sarclisa, on March 2, 2020. This medication is classified as a CD38 monoclonal antibody and is specifically used to treat multiple myeloma in adults.

This IND will enable the assessment of ADI-270, for the therapeutic intervention in relapsed/refractory renal cell carcinoma.

The U.S. Food and Drug Administration (FDA) approved Rimegepant, under the brand name Nurtec ODT, on February 27, 2020.

Scholar Rock Unveils New SRK-439 Preclinical Data Showing Notable Lean Mass Preservation and Reduced Fat Mass Rebound After Stopping GLP-1 Receptor Agonist.

The U.S. Food and Drug Administration (FDA) approved Nexlizet, a combination of bempedoic acid and ezetimibe, on February 26, 2020.

Altimmune Shares Findings on Pemvidutide's Impact on Cardioinflammatory Lipid Levels at ADA’s 84th Annual Scientific Sessions.

The U.S. Food and Drug Administration (FDA) approved bempedoic acid on February 21, 2020.

Novo Nordisk A/S: Mim8 showed better reductions in annual bleeding rates (ABR) than on-demand treatments and previous prophylaxis in haemophilia A patients.

The U.S. Food and Drug Administration (FDA) approved Eptinezumab on February 21, 2020.

In pre-clinical models, DA-1726 from NeuroBo Pharmaceuticals outperformed Survodutide in weight reduction, maintaining lean body mass, and lowering lipid levels.